Your browser is no longer supported. Please, upgrade your browser.
Settings
EPZM Epizyme, Inc. daily Stock Chart
EPZM [NASD]
Epizyme, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own0.20% Shs Outstand82.73M Perf Week-7.00%
Market Cap989.45M Forward P/E- EPS next Y-1.86 Insider Trans251.82% Shs Float58.63M Perf Month-1.81%
Income-123.60M PEG- EPS next Q-0.46 Inst Own93.10% Short Float9.52% Perf Quarter101.35%
Sales21.70M P/S45.60 EPS this Y21.30% Inst Trans9.45% Short Ratio5.59 Perf Half Y19.00%
Book/sh2.95 P/B4.05 EPS next Y12.30% ROA-50.60% Target Price18.80 Perf Year-35.87%
Cash/sh2.90 P/C4.12 EPS next 5Y38.00% ROE-58.80% 52W Range5.14 - 19.55 Perf YTD94.16%
Dividend- P/FCF- EPS past 5Y-50.90% ROI-55.00% 52W High-38.82% Beta3.14
Dividend %- Quick Ratio7.20 Sales past 5Y-20.50% Gross Margin- 52W Low132.68% ATR0.74
Employees124 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)48.70 Volatility5.52% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q44.30% Profit Margin- Rel Volume0.54 Prev Close12.08
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 BMO Payout- Avg Volume997.82K Price11.96
Recom1.60 SMA20-4.27% SMA505.69% SMA20013.40% Volume541,963 Change-0.99%
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-10-16Reiterated Mizuho Buy $20 → $18
Apr-05-16Initiated Citigroup Buy $17
Mar-14-16Upgrade H.C. Wainwright Neutral → Buy $25
Mar-10-16Reiterated Wedbush Outperform $33 → $22
Mar-10-16Reiterated Mizuho Buy $26 → $20
Mar-09-16Reiterated RBC Capital Mkts Outperform $39 → $26
Aug-06-15Reiterated Mizuho Buy $29 → $26
Jul-20-15Downgrade H.C. Wainwright Buy → Neutral $45 → $22
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Mar-13-15Reiterated Mizuho Buy $35 → $29
Sep-12-14Initiated Mizuho Buy $35
Mar-12-19 10:45AM  Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-08-19 12:14PM  Does Epizyme, Inc.s (NASDAQ:EPZM) CEO Salary Compare Well With Others? Simply Wall St.
Mar-06-19 10:16PM  Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock Business Wire
04:01PM  Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock Business Wire
Mar-05-19 06:30AM  Epizyme Announces Presentations at Upcoming March Investor Conferences Business Wire
Mar-01-19 06:41AM  Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 10:14AM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4 Zacks
Feb-26-19 06:30AM  Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire +12.05%
Feb-19-19 06:30AM  Epizyme Announces Date of Fourth Quarter and Full Year 2018 Results and Upcoming Presentation at the 8th Annual SVB Leerink Global Health Care Conference Business Wire -5.51%
Feb-14-19 12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
Feb-12-19 07:35AM  New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 06:14PM  Epizyme to File NDA for Tazemetostat in Follicular Lymphoma Zacks +5.79%
Jan-04-19 04:27PM  Why GameStop, Novavax, and Epizyme Jumped Today Motley Fool +32.78%
02:13PM  Here's Why Epizyme's Shares Are Surging 19.6% Higher Today Motley Fool
10:10AM  These 4 Healthcare Stocks Are Making Moves ACCESSWIRE
06:30AM  Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma and Provides Pipeline Updates and 2019 Guidance Business Wire
Dec-19-18 10:44PM  Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds? Insider Monkey
Dec-18-18 06:30AM  Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor Business Wire
Dec-02-18 09:30AM  Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report? Zacks
Nov-15-18 06:35AM  Epizyme Announces Conference Call to Discuss Corporate Updates Business Wire
Nov-09-18 08:00AM  Market Trends Toward New Normal in Paramount Group, Envestnet, Assurant, HubSpot, Epizyme, and Cytosorbents Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-05-18 02:20PM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3 Zacks
Nov-02-18 07:40AM  Epizyme (EPZM) Reports Q3 Loss, Lags Revenue Estimates Zacks -6.29%
06:35AM  Epizyme: 3Q Earnings Snapshot Associated Press
06:30AM  Epizyme Reports Third Quarter 2018 Financial Results and Tazemetostat Progress Business Wire
Oct-22-18 05:00AM  Epizyme Reports Positive Data on Tazemetostat in Epithelioid Sarcoma from its Phase 2 Trial Cohort at ESMO Business Wire -5.48%
Oct-18-18 01:28PM  What Kind Of Investor Owns Most Of Epizyme Inc (NASDAQ:EPZM)? Simply Wall St.
Oct-17-18 07:45AM  Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.86%
Oct-12-18 05:00AM  Big Biotech Investors Poured $29 Million Into 2 Battered Companies Barrons.com
Oct-10-18 06:45AM  Epizyme to Present Updated Data on Tazemetostat from Full Phase 2 Study Cohort in Epithelioid Sarcoma at ESMO Business Wire
Oct-05-18 04:05PM  Epizyme Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-03-18 07:54AM  The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares Benzinga
Oct-02-18 05:00PM  After-hours buzz: TPX, JCP & more CNBC -6.99%
04:01PM  Epizyme Announces Proposed Public Offering of Common Stock Business Wire
Sep-25-18 10:52AM  FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study Zacks
Sep-24-18 07:45AM  Epizyme's stock soars after FDA lifts hold on trial enrollments MarketWatch
06:30AM  Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program Business Wire
Aug-29-18 07:00AM  Epizyme to Participate in Upcoming Investor Conferences Business Wire
Aug-20-18 07:30AM  Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-05-18 11:28PM  Edited Transcript of EPZM earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-03-18 05:34PM  Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks Zacks
Aug-02-18 10:20AM  Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates Zacks -23.85%
10:07AM  Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss Zacks
09:18AM  Epizyme: 2Q Earnings Snapshot Associated Press
07:00AM  Epizyme Reports Second Quarter 2018 Financial Results and Provides Business Updates Business Wire
Jul-31-18 04:44PM  What's in Store for Epizyme (EPZM) This Earnings Season? Zacks
Jul-19-18 07:30AM  Epizyme Announces Date of Second Quarter 2018 Financial Results and Business Update Conference Call GlobeNewswire
Jun-21-18 07:25AM  Stock Performance Review on Exelixis and Three Other Biotech Stocks ACCESSWIRE -5.66%
Jun-15-18 05:30AM  Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA) GlobeNewswire -5.68%
Jun-07-18 09:54AM  Why Is Epizyme (EPZM) Up 16.2% Since Its Last Earnings Report? Zacks
Jun-06-18 07:55AM  Report: Developing Opportunities within Silicon Motion Technology, Green Brick Partners, Alliance Resource Partners, Perrigo Company plc, Epizyme, and Landec Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-03-18 09:00AM  Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO GlobeNewswire
Jun-01-18 07:30AM  Epizyme to Host Investor Conference Call to Discuss Interim Follicular Lymphoma Clinical Data GlobeNewswire
May-21-18 07:40AM  Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in China ACCESSWIRE
May-17-18 09:13AM  Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress GlobeNewswire
May-09-18 11:20AM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1 Zacks +8.45%
May-08-18 08:06AM  Epizyme: 1Q Earnings Snapshot Associated Press
08:02AM  Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss Zacks
07:30AM  Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates GlobeNewswire
06:35AM  Epizyme Inc (NASDAQ:EPZM): Does The -21.86% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
May-07-18 05:47PM  Is a Beat in Store for Epizyme (EPZM) This Earnings Season? Zacks
Apr-24-18 01:14PM  'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish Benzinga -15.03%
Apr-23-18 04:45PM  Epizyme Provides Update Regarding Tazemetostat Clinical Program GlobeNewswire
Apr-12-18 08:43AM  Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report? Zacks
Apr-11-18 04:11PM  Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up Zacks +6.27%
07:55AM  Recent Analysis Shows Photronics, Just Energy Group, Baidu, Nomura Holdings Inc ADR, KT, and Epizyme Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-09-18 06:45PM  Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology GlobeNewswire -7.24%
Mar-16-18 08:00AM  New Research: Key Drivers of Growth for GDS HOLDINGS, Nova Measuring Instruments, Magic Software Enterprises, Epizyme, United Community Financial, and Addus HomeCare Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -5.06%
Mar-13-18 09:11PM  Edited Transcript of EPZM earnings conference call or presentation 13-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
08:10AM  Epizyme (EPZM) Reports Narrower-than-Expected Q4 Loss Zacks
08:05AM  Epizyme reports 4Q loss Associated Press
07:30AM  Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones GlobeNewswire
06:30AM  Epizyme, Inc. to Host Earnings Call ACCESSWIRE
Mar-12-18 04:30PM  Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors GlobeNewswire
06:30AM  Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference GlobeNewswire
Feb-27-18 09:07AM  What's in Store for Epizyme (EPZM) This Earnings Season? Zacks
06:30AM  Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference GlobeNewswire
Feb-07-18 06:30AM  Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-10-18 05:38PM  ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax Benzinga +19.20%
10:26AM  Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making Benzinga
Dec-26-17 05:35AM  Does Epizyme Incs (NASDAQ:EPZM) Past Performance Indicate A Weaker Future? Simply Wall St.
Dec-11-17 07:31AM  Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting GlobeNewswire
Dec-10-17 10:00AM  Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting GlobeNewswire
Nov-09-17 06:30AM  Epizyme to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Nov-02-17 11:55AM  Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3 Zacks -9.91%
Nov-01-17 11:41PM  Edited Transcript of EPZM earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
05:49PM  Epizyme reports 3Q loss Associated Press
04:02PM  Epizyme Reports Third Quarter 2017 Operating Results and Company Updates GlobeNewswire
Oct-31-17 07:40AM  Featured Company News - Epizyme Presented Data from Phase-1 Trial of Tazemetostat In Children with Relapsed/Refractory INI1-Negative Solid Tumors ACCESSWIRE
Oct-30-17 11:45AM  ETFs with exposure to Epizyme, Inc. : October 30, 2017 Capital Cube
Oct-27-17 10:30AM  What to Expect From Epizyme (EPZM) This Earnings Season? Zacks
09:15AM  Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Oct-25-17 07:00AM  Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors CNW Group
06:30AM  Epizyme Announces Date of Third Quarter 2017 Financial Results GlobeNewswire
Oct-17-17 09:42AM  ETFs with exposure to Epizyme, Inc. : October 17, 2017 Capital Cube
Oct-06-17 10:50AM  ETFs with exposure to Epizyme, Inc. : October 6, 2017 Capital Cube
Oct-05-17 09:35AM  Epizyme, Inc. :EPZM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
Sep-20-17 08:31AM  Epizyme (EPZM) Looks Good: Stock Adds 7.8% in Session Zacks
Sep-19-17 06:30AM  Epizyme Announces Closing of Public Offering of Common Stock GlobeNewswire +7.84%
Sep-15-17 04:30PM  Why Blue Apron Holdings, Tailored Brands, and Epizyme Jumped Today Motley Fool +7.50%
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOTT DAVID MDirectorOct 05Buy9.00416,6673,750,0036,471,018Oct 05 06:36 PM